Samter’s Triad: State of the Art

키워드

참고문헌 (107)

1. Widal F, "First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria): 1922 (with a note on aspirin desensitization)", J Asthma, 24(5), pp.297~300 (1987)[DOI]
2. Samter M, "Intolerance to aspirin. clinical studies and consideration of its pathogenesis", Ann Intern Med, 68(5), pp.975~983 (1968)[DOI]
3. Stevenson DD, "Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes", Ann Allergy Asthma Immunol, 87(3), pp.177~180 (2001)[DOI]
4. Johansson SG, "Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003", J Allergy Clin Immunol, 113(5), pp.832~836 (2003)
5. Szczeklik A, "Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management", J Allergy Clin Immunol, 111(5), pp.913~921 (2003)[DOI]
6. Babu KS, "Aspirin and asthma", Chest, 118(5), pp.1470~1476 (2000)[DOI]
7. Szczeklik A, "Aspirin intolerance and the cyclooxygenase-leukotriene pathways", Curr Opin Pulm Med, 10(1), pp.51~56 (2004)[DOI]
8. Pfaar O, "Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements", Curr Opin Allergy Clin Immunol, 6(3), pp.161~166 (2006)[DOI]
9. Stevenson DD, "Clinical and pathologic perspectives on aspirin sensitivity and asthma", J Allergy Clin Immunol, 118(4), pp.773~786 (2006)[DOI]
10. Vally H, "The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients", Thorax, 57(7), pp.569~574 (2002)[DOI]
11. Jenkins C, "Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice", BMJ, 328(7437), pp.434~ (2004)[DOI]
12. Delaney JC, "The diagnosis of aspirin idiosyncrasy by analgesic challenge", Clin Allergy, 6(2), pp.177~181 (1976)[DOI]
13. Weber RW, "Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics", J Allergy Clin Immunol, 64(1), pp.32~37 (1979)[DOI]
14. Dursun AB, "Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis", Ann Allergy Asthma Immunol, 100(5), pp.420~425 (2008)[DOI]
15. Berges-Gimeno MP, "The natural history and clinical characteristics of aspirin-exacerbated respiratory disease", Ann Allergy Asthma Immunol, 89(5), pp.474~478 (2002)[DOI]
16. Szczeklik A, "Natural history of aspirin-induced asthma. AIANE investigators. European Network on Aspirin-Induced Asthma", Eur Respir J, 16(3), pp.432~436 (2000)[DOI]
17. Kidon MI, "Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children", Pediatrics, 116(5), pp.e675~e680 (2005)[DOI]
18. Kim JE, "The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery", Ear Nose Throat J, 86(7), pp.396~399 (2007)
19. Szczeklik A, "The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors", Clin Exp Allergy, 32(3), pp.339~342 (2002)[DOI]
20. Chavis C, "Lipoxins and other arachidonate derived mediators in bronchial asthma", Thorax, 55(Suppl 2), pp.S38~S41 (2000)[DOI]
21. Stevenson DD, "Aspirin sensitivity and desensitization for asthma and sinusitis", Curr Allergy Asthma Rep, 9(2), pp.155~163 (2009)[DOI]
22. Cowburn AS, "Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma", J Clin Invest, 101(4), pp.834~846 (1998)[DOI]
23. Adamjee J, "Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma", J Pathol, 209(3), pp.392~399 (2006)[DOI]
24. Steinke JW, "Factors driving the aspirin exacerbated respiratory disease phenotype", Am J Rhinol Allergy, 29(1), pp.35~40 (2015)[DOI]
25. Hamad AM, "Aspirin-induced asthma: clinical aspects, pathogenesis and management", Drugs, 64(21), pp.2417~2432 (2004)[DOI]
26. Gaber F, "Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma", Thorax, 63(12), pp.1076~1082 (2008)[DOI]
27. Capra V, "Molecular and functional aspects of human cysteinyl leukotriene receptors", Pharmacol Res, 50(1), pp.1~11 (2004)[DOI]
28. Hui Y, "Cysteinyl leukotriene receptors", Biochem Pharmacol, 64(11), pp.1549~1557 (2002)[DOI]
29. Jenneck C, "Pathogenesis, diagnosis, and treatment of aspirin intolerance", Ann Allergy Asthma Immunol, 99(1), pp.13~21 (2007)[DOI]
30. Sousa AR, "Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis", N Engl J Med, 347(19), pp.1493~1499 (2002)[DOI]
31. Kim SH, "CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients", Pharmacogenomics, 8(9), pp.1143~1150 (2007)[DOI]
32. Peters-Golden M, "Leukotrienes", N Engl J Med, 357(18), pp.1841~1854 (2007)[DOI]
33. Szczeklik A, "Prostaglandin E2 and aspirin-induced asthma", Lancet, 345(8956), pp.1056~ (1995)
34. Buchheit KM, "Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 137(5), pp.1566~1576 (2016)[DOI]
35. Yamashita T, "Etiology of nasal polyps associated with aspirin-sensitive asthma", Rhinol Suppl, 8, pp.15~24 (1989)
36. Sladek K, "Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge", Am J Respir Crit Care Med, 149(4), pp.940~946 (1994)[DOI]
37. Dekker JW, "Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes", Clin Exp Allergy, 27(5), pp.574~577 (1997)[DOI]
38. Choi JH, "HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population", J Allergy Clin Immunol, 113(3), pp.562~564 (2004)[DOI]
39. Sanak M, "Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma", Lancet, 350(9091), pp.1599~1600 (1997)[DOI]
40. Choi JH, "Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase", Hum Genet, 114(4), pp.337~344 (2004)[DOI]
41. Jinnai N, "Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach", Hum Mol Genet, 13(24), pp.3203~3217 (2004)[DOI]
42. 박병래, "Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics", BMB Reports, 43(6), pp.445~449 (2010), 생화학분자생물학회
43. Kim SH, "Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma", Clin Exp Allergy, 35(5), pp.585~590 (2005)[DOI]
44. Park JS, "Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics", Pharmacogenet Genomics, 15(7), pp.483~492 (2005)[DOI]
45. Kim SH, "Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis", Allergy, 64(8), pp.1221~1225 (2009)[DOI]
46. Kohyama K, "IL-13 and IL-17A gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease", Ann Allergy Asthma Immunol, 107(6), pp.510~516 (2011)[DOI]
47. Bochenek G, "Testing for aspirin hypersensitivity", Allergy, 57(7), pp.562~565 (2002)[DOI]
48. Nizankowska E, "Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma", Eur Respir J, 15(5), pp.863~869 (2000)[DOI]
49. Rachel U. Lee, "Aspirin-Exacerbated Respiratory Disease: Evaluation and Management", Allergy, Asthma & Immunology Research, 3(1), pp.3~10 (2011), 대한천식알레르기학회
50. Nizankowska-Mogilnicka E, "EAACI", GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity, 2007, pp.62(10), 1111~1118
51. Melillo G, "Report of the INTERASMA Working Group on standardization of inhalation provocation tests in aspirin-induced asthma: oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma", Allergy, 56(9), pp.899~911 (2001)[DOI]
52. Nami Shrestha Palikhe, "Update on Recent Advances in the Management of Aspirin Exacerbated Respiratory Disease", Yonsei Medical Journal, 50(6), pp.744~750 (2009), 연세대학교의과대학
53. Milewski M, "Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma", J Allergy Clin Immunol, 101(5), pp.581~586 (1998)[DOI]
54. Alonso-Llamazares A, "Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA)", Allergy, 57(7), pp.632~635 (2002)[DOI]
55. White A, "Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease", Ann Allergy Asthma Immunol, 97(2), pp.190~195 (2006)[DOI]
56. Lee RU, "Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease", Ann Allergy Asthma Immunol, 105(2), pp.130~135 (2010)[DOI]
57. Klimek L, "Aspirin intolerance: does desensitization alter the course of the disease?", Immunol Allergy Clin North Am, 29(4), pp.669~675 (2009)[DOI]
58. Daffern PJ, "Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses", J Allergy Clin Immunol, 104(3), pp.559~564 (1999)[DOI]
59. Jerschow E, "Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease", Ann Allergy Asthma Immunol, 116(4), pp.321~328 (2016)[DOI]
60. Antczak A, "Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma", Am J Respir Crit Care Med, 166(3), pp.301~306 (2002)[DOI]
61. Cahill KN, "Aspirin exacerbated respiratory disease: the search for a biomarker", Ann Allergy Asthma Immunol, 113(5), pp.500~501 (2014)[DOI]
62. Chandrasekharan NV, "COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic", antipyretic drugs: cloning, structure, and expression, 2002, pp.99(21), 13926~13931
63. Settipane RA, "Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects", J Allergy Clin Immunol, 96(4), pp.480~485 (1995)[DOI]
64. Yoshida S, "Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma", J Allergy Clin Immunol, 106(6), pp.1201~1202 (2000)
65. Szczeklik A, "Safety of a specific COX-2 inhibitor in aspirin-induced asthma", Clin Exp Allergy, 31(2), pp.219~225 (2001)[DOI]
66. Stevenson DD, "Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma", J Allergy Clin Immunol, 108(1), pp.47~51 (2001)[DOI]
67. Woessner KM, "The safety of celecoxib in patients with aspirin-sensitive asthma", Arthritis Rheum, 46(8), pp.2201~2206 (2002)[DOI]
68. Inoue K, "Cyclooxygenase-2 inhibitors in aspirin-induced asthma", Chest, 123(4), pp.1317~1318 (2003)
69. Gyllfors P, "Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib", J Allergy Clin Immunol, 111(5), pp.1116~1121 (2003)[DOI]
70. Stevenson DD, "Selection of patients for aspirin desensitization treatment", J Allergy Clin Immunol, 118(4), pp.801~804 (2006)[DOI]
71. Berges-Gimeno MP, "Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 111(1), pp.180~186 (2003)[DOI]
72. Stevenson DD, "Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes", J Allergy Clin Immunol, 98(4), pp.751~758 (1996)[DOI]
73. Kowalski ML, "Clinical efficacy of aspirin in desensitised aspirin-sensitive asthmatics", Eur J Respir Dis, 69(4), pp.219~225 (1986)
74. Rizk H, "Role of aspirin desensitization in the management of chronic rhinosinusitis", Curr Opin Otolaryngol Head Neck Surg, 19(3), pp.210~217 (2011)[DOI]
75. Hope AP, "Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 123(2), pp.406~410 (2009)[DOI]
76. Cho KS, "Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease", Otolaryngol Head Neck Surg, 151(4), pp.575~581 (2014)[DOI]
77. Swierczynska-Krepa M, "Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study", J Allergy Clin Immunol, 134(4), pp.883~890 (2014)[DOI]
78. Macy E, "Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper", Ann Allergy Asthma Immunol, 98(2), pp.172~174 (2007)[DOI]
79. Comert S, "Aspirin 300 mg", day is effective for treating aspirin-exacerbated respiratory disease, 2013, pp.68(11), 1443~1451
80. Ortega-Loayza AG, "Aspirin desensitization", challenge in 3 patients with unstable angina, 2010, pp.340(5), 418~420
81. Lee JY, "Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol, 119(1), pp.157~164 (2007)[DOI]
82. Rozsasi A, "Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily", Allergy, 63(9), pp.1228~1234 (2008)[DOI]
83. Namazy JA, "Sensitivity to nonsteroidal anti-inflammatory drugs", Ann Allergy Asthma Immunol, 89(6), pp.542~550 (2002)[DOI]
84. Arm JP, "Leukotriene receptors and aspirin sensitivity", N Engl J Med, 347(19), pp.1524~1526 (2002)[DOI]
85. Steinke JW, "Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization", J Allergy Clin Immunol, 124(4), pp.724~730 (2009)[DOI]
86. White AA, "Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment?", J Allergy Clin Immunol, 126(4), pp.745~746 (2010)[DOI]
87. Katial RK, "The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases", J Allergy Clin Immunol, 126(4), pp.738~744 (2010)[DOI]
88. Aksu K, "Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease", Allergy Asthma Proc, 35(2), pp.148~55 (2014)[DOI]
89. Dahlen SE, "Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial", Am J Respir Crit Care Med, 165(1), pp.9~14 (2002)[DOI]
90. Mastalerz L, "Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma", Allergy, 52(9), pp.895~900 (1997)[DOI]
91. Lee DK, "Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma", Eur Respir J, 24(2), pp.226~230 (2004)[DOI]
92. Ta V, "Survey-defined patient experiences with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol Pract, 3(5), pp.711~718 (2015)[DOI]
93. Wenzel S, "The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study", J Asthma, 44(4), pp.305~310 (2007)[DOI]
94. Hayashi H, "Omalizumab reduces cysteinyl leukotriene and <TEX>$9{\alpha}$<", TEX>,<TEX>$11{\beta}$<, J Allergy Clin Immunol, pp.2016, 137(5)[DOI]
95. Kolbeck R, "MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function", J Allergy Clin Immunol, 125(6), pp.1344~1353 (2010)[DOI]
96. Varricchi G, "Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs", Curr Opin Allergy Clin Immunol, 16(2), pp.186~200 (2016)[DOI]
97. Laviolette M, "Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia", J Allergy Clin Immunol, 132(5), pp.1086~1096 (2013)[DOI]
98. Hosemann W, "Surgical treatment of nasal polyposis in patients with aspirin intolerance", Thorax, 55(Suppl 2), pp.S87~S90 (2000)[DOI]
99. McMains KC, "Medical and surgical considerations in patients with Samter's triad", Am J Rhinol, 20(6), pp.573~576 (2006)[DOI]
100. Jang DW, "Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad", Laryngoscope, 124(1), pp.34~37 (2014)[DOI]
101. Havel M, "Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad", Eur Arch Otorhinolaryngol, 270(2), pp.571~578 (2013)[DOI]
102. Batra PS, "Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma", Laryngoscope, 113(10), pp.1703~1706 (2003)
103. Rotenberg BW, "Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial", Laryngoscope, 121(12), pp.2702~2705 (2011)[DOI]
104. Katotomichelakis M, "Allergic rhinitis and aspirin-exacerbated respiratory disease as predictors of the olfactory outcome after endoscopic sinus surgery", Am J Rhinol Allergy, 23(3), pp.348~353 (2009)[DOI]
105. Adelman J, "The role of surgery in management of Samter's triad: a systematic review", Otolaryngol Head Neck Surg, 155(2), pp.220~237 (2016)[DOI]
106. Loehrl TA, "Long-term asthma outcomes after endoscopic sinus surgery in aspirin triad patients", Am J Otolaryngol, 27(3), pp.154~160 (2006)[DOI]
107. Awad OG, "Asthma outcomes after endoscopic sinus surgery in aspirin-tolerant versus aspirin-induced asthmatic patients", Am J Rhinol, 22(2), pp.197~203 (2008)[DOI]

관련 논문AI추천